Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Biological diagnosis of resistance to erlotinib in a malignant pleural effusion].

Revue des maladies respiratoires - 1 Sept 2013

Rieux C, Boisdron-Celle M, Morel A, Fey L, Urban T, Hureaux J

Abstract excerpt

INTRODUCTION: The characterization of genetic abnormalities in non-small cell lung cancer (NSCLC) constitutes a theranostic revolution which is leading to rapid progress in the personalized management of this condition. CASE REPORT: We present the case of a patient with NSCLC harboring an activating mutation of the Epidermal Growth Factor Receptor (EGFR). After two years of treatment with a tyrosine kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Genes, erbB-1

Share to Pleural Effusion, Malignant

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 24034463
DOI: 10.1016/j.rmr.2013.02.010

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Biological diagnosis of resistance to erlotinib in a malignant pleural effusion].PMID 24034463Read ↗

[Detection of novel driver mutations in liquid biopsy: case report of a RET-positive lung adenocarcinoma treated with pralsetinib.]Semantic proximity Read ↗

Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutationsSemantic proximity Read ↗

Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations.Semantic proximity Read ↗

Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance.Semantic proximity Read ↗

[Osimertinib for an Elderly Patient with Adenocarcinoma of the Lung Harboring EGFR T790M Mutation Diagnosed Using a Pleural Fluid Cell Block].Semantic proximity Read ↗

[Evaluation of Consistency in detection of epidermal growth factor receptor gene T790M mutation in plasma and tumor specimens of patients with lung adenocarcinoma].Semantic proximity Read ↗

[Response of Erlotinib in Lung Adenocarcinoma Harboring EGFR Sensitive Mutation in Cerebrospinal Fluid: Case Report].Semantic proximity Read ↗

Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation.Semantic proximity Read ↗

RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.Semantic proximity Read ↗

EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report.Semantic proximity Read ↗

EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib.Semantic proximity Read ↗

Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.